VULVOVAGINAL ATROPHY: SYMPTOMS, IMPACT ON EMOTIONAL WELL-BEING, QUALITY, AND SEXUAL FUNCTION


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Vulvovaginal atrophy (VVA) at menopause is a complex of symptoms associated with the development of atrophic and dystrophic processes in estrogen-dependent vaginal tissues. VVA symptoms, such as vaginal dryness, itching, burning, and dyspareunia, are observed in 40-57% of postmenopausal women. Objective: to study the impact of the symptoms of VVA on emotional well-being, quality of life, and sexual function in postmenopausal women. Subjects and methods. The survey covered 100 women aged 40 to 75 years with a postmenopausal duration of 1 to 35 years. A study group consisted of 63 patients with diagnostically verified vulvovaginal atrophy (Group 1); a control group comprised 37 patients (Group 2). The survey involved questionnaire interviewing and laboratory diagnosis. All the patients underwent cytological examination of the vaginal wall, followed by estimation of the epithelial maturation index and vaginal pH. Results. VVA symptoms were present in two groups and statistically similar. The most common complaint was dryness reported by 60% of the respondents. As in previously conducted surveys, our respondents felt embarrassed because of vaginal discomfort (41.3 and 54.1% in Groups 1 and 2, respectively; p = 0.218), which had in turn a negative impact on the women’s emotional status. Some patients noted a decreased desire to interact with others (9.5 and 13.5 in Groups 1 and 2; p = 0.540) and deterioration of daily activity due to the presence of VVA symptoms (30 and 20% in Groups 1 and 2; p=0.218). When analyzing the quality of their sexual life, the investigators considered the indicators of only the women who were married or those who reported to have a sexual partner (Subgroups 1a and 2a). The patients of these two subgroups were age-matched (53±3.3 and 53±7.0; p = 0.749). In both the first and second subgroups, the women experienced discomfort during sexual intercourses: pain, dryness, and postcoital bleeding. During sexual intercourses, Subgroup 1a women significantly more frequently observed pain and dryness (p = 0.021 and p = 0.046). Because of this, it was possible that the patients of this subgroup were less sexually active. Among them, only 21 (44.68%) patients continued to lead a sex life; among the patients without VVA (Subgroup 2a), 24 (74.41%) women had a regular sex life (p = 0.002). More than half of the patients in Subgroup 1a reported that the symptoms of VVA were a reason for refusing to enter into intimate relationship (p = 0.021), as well as decreased libido, which in turn negatively affected interpersonal relations between the partners. Conclusion. Vaginal dryness, itching, burning, and dyspareunia frequently bother postmenopausal women, irrespective of whether they have VVA. The presence of these symptoms upsets women and causes embarrassment, which has a negative impact on their emotional status and self-rating. Vaginal discomfort deteriorates daily activity in postmenopausal women and decreases a desire to interact with others. Pain and dryness during sexual intercourses are significantly more common in women with laboratorily verified VVA, which was a reason for refusing to enter into intimate relationship and negatively affected interpersonal relations between the partners. The women with VVA had a regular sex life twice less than those in the control group.

Full Text

Restricted Access

About the authors

Angelina Vladislavovna Glazunova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: lianochka185@yandex.ru
postgraduate of gynecological endocrinology department Moscow 117997, Ac. OParina str. 4, Russia

Svetlana Vladimirovna Yureneva

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

Email: syureneva@gmail.com
MD Moscow 117997, Ac. OParina str. 4, Russia

Larisa Sergeevna Yezhova

Research Center of Obstetrics, Gynecology, and Perinatology, Ministry of Health of Russia

PhD, 1st mortem department Moscow 117997, Ac. OParina str. 4, Russia

References

  1. Nappi R.E., Kokot-Kierepa M. Vaginal Health: Insights, Views & Attitudes (VIVA) - results from an international survey. Climacteric. 2012; 15(1): 36-44.
  2. Sinha A., Ewies A.A. Non-hormonal topical treatment of vulvovaginal atrophy: an up-to-date overview. Climacteric. 2013; 16(3): 305-12.
  3. Nappi R.E., Kingsberg S., Maamari R., Simon J. The CLOSER (CLarifying Vaginal Atrophy’s Impact On SEx and Relationships) survey: implications of vaginal discomfort in postmenopausal women and in male partners. J. Sex. Med. 2013; 10(9): 2232-41.
  4. Nappi R.E., Kokot-Kierepa M. Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas. 2010; 67(3): 233-8.
  5. Bachmann G.A., Leiblum S.R., Grill J. Brief sexual inquiry in gynecologic practice. Obstet. Gynecol. 1989; 73(3, Pt1): 425-7.
  6. Балан В.Е. Урогенитальные расстройства в климактерии (клиника, диагностика, заместительная гормонотерапия): дисс.. д-ра мед. наук. М.; 1998.
  7. Есефидзе Ж.Т. Клинико-патогенетические особенности вагинальной атрофии в постменопаузе: дисс.. канд. мед. наук. М.; 2002.
  8. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013; 20(9): 888-902.
  9. Simon J.A., Komi J. Vulvovaginal atrophy (VVA) negatively impacts sexual function, psychosocial well-being, and partner relationships. In: Proceedings of the North American Menopause Society (NAMS). October 3-6 2007, Dallas, TX, USA.
  10. Sturdee D.W., Panay N.; International Menopause Society Writing Group. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric. 2010; 13(6): 509-22.
  11. Erekson E.A., Yip S.O., Wedderburn T.S., Martin D.K., Li F.Y., Choi J.N. et al. The Vulvovaginal Symptoms Questionnaire: a questionnaire for measuring vulvovaginal symptoms in postmenopausal women. Menopause. 2013; 20(9): 973-9.
  12. Castelo-Branco C., Cancelo M.J., Villero J., Nohales F., Juliá M.D. Management of post-menopausal vaginal atrophy and atrophic vaginitis. Maturitas. 2005; 52(Suppl.1): S46-52.
  13. Griebling T.L., Liao Z., Smith P.G. Systemic and topical hormone therapies reduce vaginal innervation density in postmenopausal women. Menopause. 2012; 19(6): 630-5.
  14. Parish S.J., Nappi R.E., Krychman M.L., Kellogg-Spadt S., Simon J.A., Goldstein J.A., Kingsberg S.A. Impact of vulvovaginal health on postmenopausal women: a review of surveys on symptoms of vulvovaginal atrophy. Int. J. Women’s Health. 2013; 5: 437-47.
  15. Cumming G.P., Herald J., Moncur R., Currie H., Lee A.J. Women’s attitudes to hormone replacement therapy, alternative therapy and sexual health: a web-based survey. Menopause Int. 2007; 13(2): 79-83.
  16. Schneidewind-Skibbe A., Hayes R.D., Koochaki P.E., Meyer J., Dennerstein L. The frequency of sexual intercourse reported by women: a review of community-based studies and factors limiting their conclusions. J. Sex. Med. 2008; 5(2): 301-35.
  17. North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society. Menopause. 2007; 14(3, Pt 1): 357-69; quiz 370-1.
  18. Cumming G.P., Currie H.D., Moncur R., Lee A.J. Web-based survey on the effect of menopause on women’s libido in a computer-literate population. Menopause Int. 2009; 15(1): 8-12.
  19. Gass M.L., Cochrane B.B., Larson J.C., Manson J.E., Barnabei V.M., Brzyski R.G. et al. Patterns and predictors of sexual activity among women in the Hormone Therapy trials of the Women’s Health Initiative. Menopause. 2011; 18(11): 1160-71.
  20. Avis N.E., Brockwell S., Randolph J.FJr., Shen S., Cain V.S., Ory M., Greendale G.A. Longitudinal changes in sexual functioning as women transition through menopause: results from the Study of Women’s Health Across the Nation. Menopause. 2009; 16(3): 442-52.
  21. Kingsberg S., Althof S.E. Evaluation and treatment of female sexual disorders. Int. Urogynecol. J. Pelvic Floor Dysfunct. 2009; 20(Suppl.1): S33-43.
  22. Suckling J., Lethaby A., Kennedy R. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst. Rev. 2006; (4): CD001500.

Supplementary files

Supplementary Files
Action
1. JATS XML

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies